Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 2/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28769336 | 0.99 | PARP1 (0.57) | PARP1PLA2G2AALOX15PTGS2HTR3A | |
| SCHEMBL8664917 | 0.94 | TOP2A (0.64) | PARP1PLA2G2AALOX15PTGS2HTR3A | |
| SCHEMBL2957072 | 0.90 | TOP2A (0.59) | PARP1HTR3AIKBKBTOP2AMAPT | |
| SCHEMBL2954779 | 0.87 | TOP2A (0.70) | HTR3AIKBKBTOP2AMAPTKDM4E | |
| SCHEMBL204524 | 0.85 | PARP1 (0.53) | PARP1HTR3AIKBKBTOP2AMAPT | |
| SCHEMBL206525 | 0.84 | PARP1 (0.52) | PARP1HTR3AIKBKBTOP2AMAPT | |
| SCHEMBL3710917 | 0.84 | TOP2A (0.58) | PARP1HTR3AIKBKBTOP2AMAPT | |
| SCHEMBL204764 | 0.84 | TOP2A (0.61) | PARP1HTR3AIKBKBTOP2AKDM4E | |
| SCHEMBL205454 | 0.83 | TOP2A (0.48) | PARP1HTR3ATOP2AMAPTKDM4E | |
| SCHEMBL206399 | 0.83 | HTR3A (0.53) | PARP1HTR3ATOP2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0879820-B1 | Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors | UNIV NEWCASTLE VENTURES LTD (GB) | 2001-12-12 | — | — | EP | claimed |
| US-6015827-A | Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy | NEWCASTLE UNIVERSITY VENTURES LIMITED | 2000-01-18 | — | — | US | claimed |
| EP-0879820-A1 | Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-11-25 | — | — | EP | claimed |
| JP-H09510704-A | — | — | 1997-10-28 | — | — | JP | claimed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | claimed |
| CN-1081624-C | Benzamide analogs, useful as PARP (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors | NEWCASTLE UNIV VENTURE INVEST (GB) | 2002-03-27 | — | — | CN | disclosed |
| US-6348475-B1 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| EP-0879820-B1 | Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors | UNIV NEWCASTLE VENTURES LTD (GB) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001091796-A2 | METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6316455-B1 | Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-11-13 | — | — | US | disclosed |
| US-6015827-A | Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy | NEWCASTLE UNIVERSITY VENTURES LIMITED | 2000-01-18 | — | — | US | disclosed |
| US-6015827-A | Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy | NEWCASTLE UNIVERSITY VENTURES LIMITED | 2000-01-18 | — | — | US | disclosed |
| EP-0879820-A1 | Benzamide analogues, useful as PARP (ADP-Ribosyltransferase, ADPRT) DNA repair enzyme inhibitors | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-11-25 | — | — | EP | disclosed |
| US-5756510-A | POTENTIATE EFFECTS OF CYTOTOXIC DRUGS OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-26 | — | — | US | disclosed |
| CN-1143358-A | Benzamide analogs, useful as parp (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors | UNIV NEWCASTLE VENTURES LTD (GB) | 1997-02-19 | — | — | CN | disclosed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | PARP1 2/4885PLA2G2A 2020/4885ALOX15 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.